Basecamp Research, a London-based company that uses AI models trained on genomic data to design medicines, raised an oversubscribed $140m Series C round led by S32, the company announced on 23 September 2026.
Nvidia's venture arm NVentures, the Anthology Fund run by Menlo Ventures and Anthropic, Catalio Capital Management, the NATO Innovation Fund, the Rockefeller Foundation, European Tech Collective, the UK government's Sovereign AI unit, Firebrand River Capital, King Philanthropies, Redalpine, Singular and True Ventures also took part, according to Tech.eu and GEN. Roche vice-chairman André Hoffmann invested as well.
The company did not publish a valuation. Tech Funding News reported that the round valued Basecamp at $800m, more than three times its last known valuation. Tech.eu put total funding raised at $225m.
“We believe the future of medicine lies in reprogramming the body to repair itself.”Glen Gowers, Co-founder and CEO, Basecamp Research
What Basecamp Research does
Basecamp builds biological foundation models called EDEN, short for "environmentally-derived evolutionary network". The models are trained on what the company calls the world's largest proprietary genomic dataset, the Trillion Gene Atlas, gathered through partnerships in more than 30 countries. GEN reported that the atlas was built with Nvidia, Anthropic, PacBio and Ultima Genomics.
The company's first therapeutic focus is in vivo cell therapy: changing a patient's cells inside the body rather than extracting, engineering and reinfusing them. EDEN designs long DNA sequences, and Basecamp pairs them with large serine recombinases, enzymes that insert DNA at precise points in the genome. Its targets include cancer and autoimmune disease.
In a preprint posted in January and cited by GEN, Basecamp reported that half of the EDEN-generated recombinases it tested were active in human cells. The company said the new round followed strong preclinical results across several disease areas, but it has not said when it expects its first trial to begin.
Who invested
S32, a Palo Alto venture firm founded by GV founder Bill Maris, led the round. S32 general partner Andy Conrad, a former chief executive of Verily, joined Basecamp's board, according to GEN.
Tech.eu described NVentures, the Anthology Fund, Firebrand River Capital, King Philanthropies and Redalpine as returning investors, and Catalio, the NATO Innovation Fund, the Rockefeller Foundation, European Tech Collective and Sovereign AI as new ones. Tech Funding News named Singular and True Ventures among the returning backers. Joséphine Kant, head of ventures at Sovereign AI, told Tech.eu the founders could have built the company anywhere but chose the UK.
"We believe the future of medicine lies in reprogramming the body to repair itself," said Glen Gowers, Basecamp's co-founder and chief executive.
What the money is for
Basecamp said it would use the funding to train a new generation of EDEN models and to push its AI-designed therapies, starting with in vivo cell therapy, toward clinical development.
The company was founded in 2019 by Gowers and Oliver Vince, who both hold doctorates. Its origins trace to an expedition that year to Iceland's Vatnajökull ice cap, where the founders ran what Tech.eu described as the first off-grid DNA sequencing operation. Basecamp appointed former Biogen executive Richard Pearce as chief business officer in April.
The funding so far
According to Tech Funding News, Basecamp raised a $19.8m Series A in December 2022 led by Systemiq Capital and a $60m Series B in October 2024 led by Singular. Reports differ slightly on the running total: Tech.eu gave $225m including the Series C, while Tech Funding News put it at just under $220m.
Company website: basecamp-research.com